Viking Therapeutics (VKTX) Operating Expenses (2014 - 2026)

Viking Therapeutics has disclosed Operating Expenses across 13 years of filings, most recently posting $164.1 million for Q1 2026.

• Operating Expenses for Q1 2026 came in at $164.1 million, up 195.89% year-over-year; the trailing twelve-month figure through Mar 2026 was $502.0 million (up 191.32% YoY), and the FY2025 annual result was $393.3 million, up 160.63% from the prior year.
• Operating Expenses came in at $164.1 million for Q1 2026 at Viking Therapeutics, roughly flat from $164.7 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $164.7 million in Q4 2025 to a low of $16.2 million in Q3 2022.
• The 5-year median for Operating Expenses is $34.1 million (2024), against an average of $51.7 million.
• Across the five-year window, Operating Expenses increased 13.45% in 2022 and jumped 256.28% in 2025, its largest moves.
• Viking Therapeutics' Operating Expenses stood at $20.3 million in 2022, then surged by 44.38% to $29.3 million in 2023, then jumped by 57.89% to $46.2 million in 2024, then surged by 256.28% to $164.7 million in 2025, then slipped by 0.37% to $164.1 million in 2026.
• The last three Operating Expenses figures came in at $164.1 million (Q1 2026), $164.7 million (Q4 2025), and $98.6 million (Q3 2025), per Business Quant data.